Mild hypothermia (32°C) is routinely used in medical practice to alleviate hypoxic ischemic damage, however, the mechanisms that underlie its protective effects remain uncertain. Using a systems approach based on genome-wide expression screens, reporter assays and biochemical studies, we find that cellular hypothermia response is associated with the augmentation of major stress-inducible transcription factors Nrf2 and HIF1Α affecting the antioxidant system and hypoxia response pathways, respectively. At the same time, NF-κB, a transcription factor involved in the control of immune and inflammatory responses, was not induced by hypothermia. Furthermore, mild hypothermia did not trigger unfolded protein response. Lower temperatures (27°C and 22°C) did not activate Nrf2 and HIF1A pathways as efficiently as mild hypothermia. Current findings are discussed in the context of the thermodynamic hypothesis of therapeutic hypothermia. We argue that the therapeutic effects are likely to stem both from metabolic suppression (inhibitory component) and augmentation of stress tolerance (activating component). We argue that systems coping with cellular stressors are plausible targets of therapeutic hypothermia and deserve more attention in clinical hypothermia research.
Introduction
Mild therapeutic hypothermia of 32-35°C has shown consistent benefits against brain injuries at the experimental level [1] [2] [3] [4] . Furthermore, it also improves neurologic outcome of outside hospital cardiac arrest survivors [5, 6] and neonatal hypoxia ischemia [7, 8] . A number of studies in both experimental animal models and patients have demonstrated the efficacy of moderate hypothermia initiated a few hours after severe ischemia or circulatory arrest in reducing the subsequent neuronal death and improving behavioral recovery [5, [9] [10] [11] [12] . However, not all patients may benefit from therapeutic hypothermia. While it has been shown to provide protection in cardiac arrest and neonatal encephalopathy, clinical trials for cardio-protection in myocardial infarction showed beneficial effects only in limited subgroups [13] [14] [15] [16] .
It seems reasonable to assume that, at least partly, negative outcomes from clinical trials can be attributed to our ignorance about the therapeutic mechanisms of hypothermia and necessary conditions for its efficacy. Therapeutic hypothermia has been extensively studied in the laboratory, but most of the studies focus on its applications and efficacy in animal models. Consequently, little evidence is provided to advance our understanding of the underlying mechanisms. Ischemia and reperfusion are time-sensitive processes [17, 18] and a major problem with therapeutic hypothermia is instituting it within a narrow window of opportunity. Ongoing clinical trials are focused on figuring out the depth [14, 19, 20] and duration [21] [22] [23] of hypothermia including how to standardize re-warming [24] [25] [26] [27] , prevent and reduce side effects [11, 28, 29] , and how to identify patients most likely to benefit from therapeutic hypothermia. Clinical trials and animal studies help to improve hypothermia treatment, but relatively little knowledge has accumulated on why hypothermia provides any protection at all apart from inducing metabolic depression [30] . From a research standpoint, finding molecular mechanisms behind the therapeutic effect of cooling is of paramount importance, as it will pave the way for designing drugs targeting therapeutically relevant pathways without the confounding effects associated with body cooling.
Here, we survey the effect of hypothermia on cellular stress pathways that have the potential to extend tolerance to ischemia reperfusion injury. Our study indicates that, contrary to the thermodynamic hypothesis, which implies the slowing down of molecular processes by cooling, mild hypothermia is capable of triggering wide-spread induction of gene expression resulting in augmented stress response.
Materials and methods

Cell lines
HeLa cells (CCL-2) were purchased from ATCC and used for gene expression, glutathione, cell viability, western blot and luciferase reporter activity analysis. HIF luciferase reporter HeLa stable cell line (SL-0023, Signosis) and NF-κB luciferase reporter HepG2 stable cell line (SL-0017, Signosis) were used for luciferase reporter activity assay and gene expression analysis. ARE luciferase reporter HepG2 stable cell line (60513) was purchased from BPS Bioscience and used for gene expression, cell viability, western blot and luciferase reporter activity analysis. Mouse embryonic fibroblasts (MEFs) (Millipore) were used for gene expression, glutathione, and cell viability analysis.
All cell lines, except MEFs were cultured in low glucose MEM (MEM-STA, Capricorn Scientific) supplemented with 10% FBS (2050-1, PAN Biotech), 1 × penicillin/streptomycin (2007, Smart Media) at 37°C in a 5% CO 2 and then switched to 32°C incubator in 5% CO 2 during hypothermia experiment.
Isolation of mouse embryonic fibroblasts
To isolate Nrf2-KO (B6.129×1-Nfe2l2 tm1Ywk /J, 0017009, The
Jackson Laboratory) MEFs, pregnant mice were sacrificed at 15.5 dpc by cervical dislocation. Embryos were dissected into a 100-mm dish with PBS (2002, Smart Media), head and red organs were removed, and washed with PBS three times. Embryos were placed in a clean Petri dish and the tissue was minced using a sterile razor blade. 1 mL of 0.25% trypsin/EDTA (25200056, Gibco, Thermo Fisher Scientific) per embryo was added and Petri dish was incubated for 10 min at 37°C. After 10 min of incubation, cells were dissociated by pipetting up and down. Again, 1 mL of 0.25% trypsin/EDTA per embryo was added followed by 10 min incubation at 37°C. This step was repeated 3 times. Trypsin was inactivated by adding 1 volume of MEF medium. MEFs were cultured in high glucose DMEM (E15-883, PAA) supplemented with 10% FBS, 1 mM sodium pyruvate (S11-003, PAA), 1 × penicillin/streptomycin (1377475, Gibco, Thermo Fisher Scientific), and 2 mM Glutamax. Cells from 2 embryos were pooled in 100-mm Petri dish coated with 0.1% gelatin and incubated overnight. Next day, media was changed and cells were grown to confluency. P0 cells were frozen or continued to grow.
Treatments
All treatments were performed for 8 h at 37°C or 32°C. The following concentrations were used for treatments: tert-BHQ (150-500 µM), DL-Sulforaphane (3 µM), N-acetylcysteine (8 mM), brefeldin A (5 µg/mL), tunicamycin (5 µg/mL), cobalt (II) chloride hexahydrate (100 µM), and recombinant human TNF-α (20 ng/mL).
Tert-BHQ (112941), DL-Sulforaphane (S4441), brefeldin A (B7651) and tunicamycin (T7765) were dissolved in DMSO (A3672; PanReac AppliChem) with final concentrations ranging from 0.01 to 0.1%. Nacetylcysteine (A9165) and recombinant human TNF-α (570104) were dissolved in PBS. Cobalt (II) chloride hexahydrate (255599) was dissolved in milli-Q water.
All compounds, except for recombinant human TNF-alpha (BioLegend) were purchased from Sigma Aldrich.
Luciferase-reporter assay
HeLa cells and HepG2-NF-κB stable cells were seeded at a density of 50,000 cells/well onto 12-well plates, grown overnight, and co-transfected with 100 ng renilla and 100 ng firefly luciferase vectors by Effectene Transfection Reagent (301425, Qiagen). The following luciferase vectors were used: pRL-TK (E2241, Promega), pRL-CMV (E2261, Promega), p5xATF6-GL3 (11976, Addgene) or pd2-EYFP-N1 (Clontech). The activities of firefly and renilla luciferase were measured using the Dual Luciferase Reporter Assay System (E1980, Promega) according to manufacturer's protocols.
Stable cell lines expressing luciferase reporter were plated at a density of 80,000 cells/well in 12-well plates and grown overnight. After experimental treatment the cells were harvested and analyzed for luciferase activity using Firefly Luciferase Assay (30003-2, Biotium).
The luminescence was quantified using the VICTOR Multilabel Plate Reader (PerkinElmer). Luminometer was programmed to provide a 10-second pre-read delay, followed by a 5-second measurement period.
Protein extraction
After washing with PBS, cells were lysed in 1 × passive lysis buffer (E1941, Promega) with gentle shaking at RT for 15 min. The extracts were centrifuged at 12,000 ×g for 30 s at 4°C and stored at −80°C. Protein concentration was determined with BCA method (Pierce BCA Protein Assay Kit, Thermo Scientific) according to manufacturer's protocol.
Western blotting
Proteins extracted from HeLa-HIF stable cells were used to study HIF1Α (hypoxia-inducible factor 1A) protein expression in response to hypothermia (32°C) or CoCl 2 . Proteins extracted from HepG2-ARE stable cells were used to study Nrf2 (nuclear factor erythroid 2-related factor 2) protein expression in response to hypothermia (32°C) or tert-BHQ. Protease inhibitors (78430, ThermoFisher Scientific) were added to the lysis buffer after removing an aliquote for the luciferase activity assay. Equal amounts of protein (8 µg) were electrophoresed and transferred to a nitrocellulose membrane using the NuPAGE Electrophoresis System (Life Technologies). Membranes were incubated overnight at 4°C with primary antibodies: rabbit anti-HIF1A antibody (1:2000) (NB100-479, Novus) or rabbit anti-Nrf2 antibody (1:1000) (ab62352, Abcam) and mouse-anti beta-actin (1:10,000) (sc-47778, Santa Cruz) as a loading control. Next day, membranes were probed for 1 h at RT with fluorescent conjugated secondary antibodies goat antirabbit antibody (1:40000 for rabbit anti-HIF1A antibody and 1:5000 for rabbit anti-Nrf2 antibody) (35569, Jackson ImmunoResearch) and goat anti-mouse antibody (1:15000) (A21057, Invitrogen).
Western blotting signals were detected by using the LI-COR Odyssey CLx system (LI-COR Biotechnologies). Images were converted to grayscale and band intensities were quantified in Image Studio Lite v 3.1.4 (LI-COR Biotechnologies).
Quantitative real-time reverse transcription PCR
Cells were plated at a density of 1 million cells in 100-mm culture dishes or 400,000 cells in 6-well plate. On the next day, cells were incubated at 22°C, 27°C, and 32°C to initiate hypothermia or kept at 37°C for various durations followed by extraction of RNA with TRIzol® reagent (15596026, Thermo Fisher Scientific). One microgram of total RNA was used for first strand cDNA synthesis using Random Hexamers (LGC Biosearch Technologies or N8080127, Invitrogen) and SuperScript III Reverse Transcriptase (18080044, Thermo Fisher Scientific). Every reaction was made in four parallel samples to minimize possible errors. All reactions were performed in a final volume of 10 μL, using 5 ng of cDNA. Primers and probes for qPCR assay were purchased from Applied Biosystems or designed for the detection of specific transcripts (LGC Biosearch Technologies) (Supplementary Table S1 ). Expression level of Ywhaz or HPRT was used as internal reference for MEFs or HeLa and HepG2 cells, respectively. Real-time qPCR was performed using TaqMan Gene Expression Master Mix 
Glutathione levels
The levels of total glutathione and GSSG were evaluated in HeLa, wild type and Nrf2 KO MEFs using the GSH/GSSG-Glo™ Assay (V6612, Promega). Cells were plated at 10,000 cells/well in 100 μL culture media in 96-well luminometer-compatible tissue culture plates, grown overnight at 37°C in a 5% CO 2 culture incubator, and subjected to normothermia (37°C) or hypothermia (32°C) for 24 h. Luminescence was measured using the Tecan Sunrise machine.
Cell viability assay
Cell viability of MEFs, HeLa and HepG2-ARE cells was determined using of Cell Proliferation Reagent WST-1 (05015944001, Sigma Aldrich). Briefly, cells were plated at a density of 10,000/well in 100 μL culture media in 96-well plate. Next day, the cells were exposed to normothermia (37°C) or hypothermia (32°C) for 24 h in a humidified tissue culture incubator. After 24 h, culture media was changed to treat the cells with tert-BHQ for 3 h. Finally, WST-1 reagent was added to wells according to the manufacturer's instructions and incubated for additional 2 h. Absorbance was measured at 450 nm. Reference wavelength was 690 nm. To qualify independent experiments for subsequent statistical analysis it was required that the effect of tert-BHQ on the viability of cells pre-incubated at 37 C lie between 0.25 and 0.75 of the vehicle control viability.
Microarray experiments
One million primary MEFs (Millipore) were seeded onto 100-mm culture dishes and grown (atmospheric oxygen, 5% CO 2 at 37°C) in DMEM (high glucose 4.5 g/l, supplemented with 10% FBS and L-glutamine, PAA) until 60-70% confluent. Hypoxia was initiated by lowering oxygen concentration to 1% in a multi-gas incubator (Sanyo). Hypothermia was initiated by lowering temperature in the incubator to 32°C. The experiment was carried out in five biological replicates per experimental condition. After 24 h, RNA was extracted from the cells by Trizol® (Life) followed by expression profiling according to manufacturer's protocols. Briefly, 50 ng of total RNA from each sample was amplified using the OvationPico WTA system V2 (Nugene). Fragmentation and biotin labeling was done using the Encore-Ovation cDNA Biotin Module (Nugene). The labeled samples were hybridized to the Mouse Exon 1.0 ST array (Affymetrix). The arrays were washed and stained with phycoerytrin conjugated streptavidin (SAPE) using the Affymetrix Fluidics Station® 450, and the arrays were scanned in the Affymetrix Gene Array® 3000 scanner to generate fluorescent images, as described in the Affymetrix Gene Chip® protocol. Cell-intensity (CEL) files were generated in the Gene Chip® Command Console® Software (AGCC) (Affymetrix).
Microarray data analysis
Differential gene expression was estimated directly from CEL files using DEMI [31] as implemented in R package version 1.0 (https:// CRAN.R-project.org/package=demi). FDR-adjusted differential expression p-values were provided by the DEMI package using a variant of FDR method, which accounts for statistical dependence between the observed variables [32] . Differential expression estimates with FDR values below 0.001 were considered statistically significant. Ensemble gene ID-s of significantly differentially expressed genes were submitted to g:Profiler [33] for functional interpretation. Lists of up-and downregulated genes were submitted separately. KEGG pathways [34] and TRANSFAC transcription factor binding sites [35] with corrected pvalues below 0.001 were considered as significantly over-represented in the gene list.
Results
Large-scale gene expression profiling of MEFs revealed 3240 upregulated and 962 down-regulated genes in response to mild hypothermia (Supplementary file 1 -Microarray analysis). Bioinformatic analysis of regulatory sequence motifs identified 85 unique transcription factors with significantly over-represented binding sites in promoter regions of hypothermia-induced genes (Supplementary file 1 -Microarray analysis). RNA-transport was the only enriched KEGG pathway among hypothermia-induced genes concordant with the notion that the two best-studied hypothermia-responsive genes (Cirbp and Rbm3) encode RNA-binding proteins [36] [37] [38] . In comparison, using the same methodology on cells treated 24 h with 1% O2 hypoxia, which is known to extensively remodel gene expression [39, 40] , resulted in the up-regulation of 335 and down-regulation of 477 genes (Supplementary file 1 -Microarray analysis). Bioinformatic analysis identified three transcription factors (Hif1a, ZF5 and Sp1) with significantly over-represented binding sites in promoter regions of hypoxia-induced genes (Supplementary file 1 -Microarray analysis). As expected, significant enrichment of genes related to HIF1 signaling pathway, glycolysis and pentose phosphate pathway was identified by functional annotation analysis of hypoxia-induced genes (Supplementary file 1 -Microarray analysis). These results demonstrate more widespread effects of hypothermia on gene expression than initially anticipated and present an extensive list of transcription factors, which are predicted to be hypothermia-responsive (Supplementary file 1 -Microarray analysis) .
In order to provide an independent validation of the hypothesis that hypothermia is able to activate gene expression, we performed reporter experiments in human cell lines transfected with CMV promoter driven luciferase. CMV promoter is a strong activator of gene expression in mammalian cells and contains binding sites of several activating transcription factors including CREB/ATF, NF-κB, AP1, ETS and SP1 [41, 42] . Based on the TRANSFAC database of transcription factor DNA binding motifs, we found 173 and 75 high confidence sites on CMV and HSV-TK promoters, respectively (Supplementary file 2 -TF binding sites). Bioinformatic analysis suggested that some transcription factors binding to the CMV promoter (most notably CREB/ATF1) had overrepresented motifs in the promoters of hypothermia-susceptible genes as identified in the genome-wide expression screen (Supplementary file 2 -TF binding sites). Luciferase driven by HSV-TK, a considerably weaker viral promoter, was used as an additional comparison. Mild hypothermia significantly induced the activity of both CMV and TK reporters up to 2.5 fold and 1.8 fold, respectively, above the normothermic level (Fig. 1) . These results provide further evidence to suggest that mild hypothermia can act as an activator of gene expression.
As the discovery of therapeutically relevant effects of hypothermia is of primary interest, we proceeded to test whether hypothermia can induce responses, which are known to mitigate cellular stress. Production of reactive oxygen species during hypoxia-reperfusion has been suggested as a possible mechanism of hypoxic injury [43] [44] [45] [46] . We investigated whether hypothermia could activate the antioxidant system. Microarray analysis indicated that several genes of the glutathione, thioredoxin and sulfiredoxin systems were upregulated after 24 h of hypothermia in wild-type MEFs (Supplementary file 1 -Microarray analysis). qRT-PCR revealed the upregulation of glutamate-cysteine ligase catalytic subunit (Gclc) and thioredoxin reductase 1 (Trxr1) at 8 h after the onset of hypothermia (Fig. 2A, C) . Upregulation Fig. 3 . Effect of hypothermia (24 h) on total cellular glutathione (A) and glutathione disulfide (GSSG) levels (B), and expression of key genes of glutathione (GCLC) (C), and thioredoxin systems (TRXR1) (D) in HeLa cells. Expression of cold-inducible gene CIRBP was used as positive control for hypothermic effect (E). Mean values (+SEM) from three independent experiments are shown (n = 3). Statistical analysis was performed with Student's t-test. *, p < 0.05; **, p < 0.01 when compared with controls at 37°C. of Gclc, sulfiredoxin 1 (Srxn1) and glutathione synthetase (Gss) was evident at 24 h of hypothermia (Fig. 2B, E, F) . The fact that Nrf2 is the master regulator of antioxidant gene expression prompted us to study hypothermia response in Nrf2-deficient MEFs. As expected, the expression levels of the studied antioxidant genes were significantly reduced in Nrf2-deficient cells. Gclc and Trxr1 did not respond significantly to hypothermia in Nrf2-deficient cells (Fig. 2B, D) . Srxn1 and Gss were significantly induced by hypothermia even in the absence of Nrf2 (Fig. 2E, F) suggesting that, in selected cases, hypothermia can induce antioxidant gene expression by Nrf2-independent mechanisms.
In order to ascertain whether the apparent induction of glutathione system genes could translate into relevant biochemical changes, cellular glutathione, the major intracellular antioxidant, was measured by the glutathione-S-transferase based enzymatic assay (Promega). Total glutathione, comprised of reduced (GSH) and oxidized forms (GSSG), was significantly higher in wild-type MEFs after 24 h of hypothermia when compared to normothermic controls. The opposite pattern was observed in Nrf2-deficient MEFs where total glutathione level was lower in hypothermic cells (Fig. 2H ). These observations suggest that Nrf2 is required for hypothermia-induced increase of cellular glutathione in MEFs. GSSG level was lower in hypothermic wild-type MEFs when compared to normothermic controls suggesting that hypothermia increases antioxidant potential while lowering oxidative stress (Fig. 2I) . GSSG was undetectable in Nrf2-deficient cells presumably due to the low level of total glutathione. Hypothermic treatment of HeLa cells was associated with increased total glutathione (Fig. 3A) and increase in the expression of GCLC and TRXR1 (Fig. 3C-D) . Hypothermia had no effect on GSSG (Fig. 3B) suggesting, once again, that hypothermia does not lead to elevated oxidative stress. To establish that hypothermic pretreatment can be protective, three different cell lines were subjected to 24 h of hypothermia followed by oxidative stress and quantification of cell viability (Fig. 4A-C) . We found that in MEF and HeLa cells, hypothermic pretreatment mitigated the effects of oxidative stress resulting in higher viability when compared to normothermic pretreatment. In sum, we found evidence for increased levels of glutathione and cell-type dependent increase in the resistance to pharmacologically induced oxidative stress after hypothermic pre-incubation.
In order to gain insight into the dynamics of Nrf2 induction, HepG2 cells constitutively expressing Nrf2 luciferase reporter were subjected to increasing durations of hypothermia. In parallel, antioxidant gene expression was monitored with real-time qPCR. Nrf2 reporter activity peaked at 8 h and declined below the baseline level by 24 h (Fig. 5A) . The expression dynamics of antioxidant system genes GCLC and TRXR1 (Fig. 5B-C) correlated positively with Nrf2 reporter activity (average Pearson Product-Moment correlation 0.86). The accuracy of Nrf2 reporter assay was confirmed by oxidative stress-inducing agents tert-BHQ and DL-Sulforaphane, which increased Nrf2 reporter activity and antioxidant N-acetylcysteine, which decreased it (Fig. 5E) . No change in the expression of Nrf2 protein was observed after hypothermia on Western blot (Fig. 5F ) suggesting that hypothermia associated increase in Nrf2 activity might be due to a post-translational mechanism.
Next, we focused on HIF1Α, the major oxygen-dependent transcriptional activator [39, 40, 47, 48] , to explore the interplay between hypoxia-sensitive stress mechanisms and hypothermia. Under normoxic conditions, HIF1Α reporter activity increased monotonically in time when exposed to increasing durations of hypothermia (Fig. 6A) . Marked amplification of HIF1Α activity by hypothermia was observed in CoCl 2 -treated cells and N-acetylcysteine abolished this effect (Fig. 6B) . Hypothermia in isolation increased HIF1Α protein abundance modestly but significantly as measured by Western blot. When hypothermia was applied together with CoCl 2 , however, HIF1Α protein induction was amplified reminiscent of a synergistic effect (Fig. 6C) . Gene expression analysis of HIF1Α target genes after 24 h of normoxic hypothermia revealed no activation of BCL2 interacting protein 3 (BNIP3) and vascular endothelial growth factor A (VEGFA) (Fig. 6D-E) , which are commonly induced under oxygen deprivation. These findings suggest that hypothermia can augment the activation of HIF1Α in hypoxiamimicking conditions. Furthermore, in normoxic settings, hypothermia increases HIF1A activity without producing a downstream response typical of oxygen deprivation.
Previous studies in animal models have suggested that relatively small decreases in body temperature are as protective as lower temperatures while not providing a mechanistic rationale for such observations [49, 50] . We subjected cells to a temperature titration curve from 37°C to 22°C in 5°C steps and measured the effect on Nrf2 and HIF1A activities and their downstream targets. Incubation at 27°C or 22°C did not increase Nrf2 and HIF1A transcription factor activities above the levels found at 32°C (Fig. 7A) . Similarly, GCLC, TRXR1 and BNIP3 gene expression levels did not exhibit consistent temperaturedependent increase below 32°C (Fig. 7B-D ). Incubation at 22°C had no effect on Nrf2 activity and its downstream targets suggesting no additional benefits from lowering the temperature further.
Ischemic hypoxic injury perturbs endoplasmic reticulum (ER) homeostasis, leads to ER stress and consequent activation of unfolded protein response (UPR) [51, 52] . As hypothermia can decrease protein synthesis [53] [54] [55] , possibly ameliorating ER-stress, we studied its effect on transcriptional activators, which bind to the mammalian endoplasmic reticulum stress response element (ERSE). No increase in ERSE reporter activity (Fig. 8A ) or in the level of X-box binding protein 1 (XBP1) spliced isoform (Fig. 8B) , which is translated to a potent transcription factor that binds to ERSE [56] , was found in response to hypothermia. ER stress inducers tunicamycin and brefeldin A increased ERSE-driven luciferase activity approximately 1.5-1.65-fold (Fig. 8A) . Furthermore, the induction of ERSE reporter activity by ER stress inducing compounds was attenuated by hypothermia (Fig. 8A) suggesting that hypothermia is more likely to alleviate than to facilitate ER stress.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor plays a major role in inflammation and immune response. It is also involved in cell growth and apoptosis [57] [58] [59] [60] .
Hypoxia and ROS production both modulate NF-κB response [61] [62] [63] . We found tumor necrosis factor alpha (TNFa), a pro-inflammatory cytokine, to activate NF-κB reporter activity 11-fold. In comparison, 1.6-fold induction of NF-κB reporter by hypothermia (Fig. 9A) was not significantly different from the baseline (see HSV-TK reporter in Fig. 1A) . The expression level of cyclooxygenase 2 (COX2) gene, a downstream target of NF-κB, appeared to be decreased by hypothermia (Fig. 9B) supporting the notion that hypothermia is not a primary inducer of pro-inflammatory response in cells.
Discussion
As hypothermia has become a routine clinical therapy for specific hypoxic/ischemic conditions worldwide [5] [6] [7] [8] 10] , questions have arisen regarding the efficacy of current cooling protocols in providing optimal protection. In the past two years, a number of reviews have addressed this issue while paying little attention to the therapeutic mechanisms [64] [65] [66] [67] . Only a handful of studies have previously studied the role of signaling pathways in the therapeutic effects of hypothermia [68] [69] [70] and the widely accepted mechanistic explanation is lacking in molecular detail. In general, proposed mechanisms rely on the conjecture that the reduction of metabolic demand in response to hypothermia leads to decreased oxidative stress, apoptosis, autophagy and inflammation [69, 70] . Let us call this conjecture the thermodynamic hypothesis. First, one should note that apoptosis, autophagy and inflammation are likely to be secondary events triggered by cellular damage and, hence, it is not clear from the hypothesis whether therapeutic hypothermia affects these processes directly or by alleviating the root causes of cellular damage. Oxidative stress can be a potential root cause and hypothermia could mitigate it either by reducing the production of reactive oxygen species (e.g. by reducing electron leak from the electron transport chain) or by enhancing the antioxidant response (e.g. by up-regulating reduced glutathione).
There is, however, a more fundamental problem, which casts doubt on the thermodynamic hypothesis as a whole. If the thermodynamic hypothesis was to hold, one would expect larger therapeutic effects at lower temperatures (i.e. a positive correlation between therapeutic efficacy and temperature reduction) since it is well known that the metabolic rate of tissue is positively correlated with body temperature (not considering hyperthermia) [71, 72] . Substantial body of evidence stands in conflict with this prediction, however, as the effect of therapeutic hypothermia peaks at around 32°C in mammals and no clear benefits arise from decreasing the temperature further [5, 6, [73] [74] [75] [76] . In line with these observations, we found no additional gain in HIF1A/Nrf2 activity and corresponding target gene expression at 27 and 22°C when compared to 32°C. These observations suggest a more complicated model where the efficacy of hypothermia possibly depends on a mechanism with inhibitory (e.g. the slowing down of metabolic rate) and activating (e.g. activation of stress mitigation pathways) components with the highest therapeutic effect emerging in the window of mild hypothermia (32-35°C). Our experiments with mild hypothermia revealed large-scale rearrangements of gene expression in cell culture concomitant with the activation of transcription factors with potentially therapeutic downstream effects. It is conceivable that mild hypothermia is accompanied by metabolic adaptation, which boosts resilience to oxidative stress to deal with the negative effects of hypoxia and decreased energy expenditure [23, [77] [78] [79] [80] . In hibernating species such as ground squirrels and bats, for example, metabolic adaptation to energy restriction has been shown to include upregulation of antioxidant proteins and glutathione [81] [82] [83] .
Our experiments in cell culture indicate that mild hypothermia triggers a temporary induction of Nrf2, the master regulator of antioxidant response, and its target genes 8 h after the onset followed by an increase in reduced glutathione level which is sustained at least 24 h.
Since the levels of oxidized glutathione were not affected by hypothermia, the up-regulation of cellular glutathione should be interpreted as an increase in antioxidant potential (i.e. a proactive effect) and not a reaction to elevated oxidative stress. Furthermore, we found that hypothermic pretreatment (24 h) increased the viability of mouse embryonic fibroblasts and HeLa cells subjected to oxidative stress. To our knowledge, we are the first to report evidence that hypothermia effect can translate into the activation of the antioxidant system on three levels of the hierarchy 1) Nrf2 transcription factor activation 2) up-regulation of Nrf2 target genes 3) up-regulation of reduced glutathione.
Another therapeutically relevant effect of hypothermia was revealed in our experiments with HIF1 reporter, where hypothermia amplified HIF1 induction when applied together with the hypoxia-mimetic CoCl 2 . Hypothermic facilitation of HIF1 response to hypoxic stress is likely to Fig. 8 . Induction of ERSE-dependent luciferase reporter in HeLa cells in response to hypothermia (A). Activity is reported with respect to the vehicle control group at 37°C. ER-stress inducing compounds brefeldin A (5 µg/mL) and tunicamycin (5 µg/mL) were used as positive controls. All treatments were performed for 8 h. Expression of XBP1, an Atf6-inducible gene, in HeLa cells in response to hypothermia (24 h) (B). Mean values (+SEM) of three independent experiments are shown (n = 3). Statistical analysis was performed with Student's t-test. *, p < 0.05; **, p < 0.01 when compared with corresponding vehicle controls at 37°C. speed up the cascade of metabolic adaptations such as switching to anaerobic ATP production by diverting glucose degradation to lactate instead of pyruvate and reduction of mitochondrial mass [84, 85] .
On the other hand, hypothermia had negligible impact on the activity ER stress and NF-kB reporters suggesting that immune signaling [86] [87] [88] and ER stress pathways [89, 90] are unlikely to be among the primary targets of therapeutic hypothermia in cells.
Conclusion
Traditionally, hypothermia is considered as a passive rather than active agent in shaping cellular physiology. Here, we present a comprehensive portrait of transcriptional regulation in response to mild hypothermia while also showing that it translates to the activation of selected stress-response pathways and increased resistance to oxidative stress in three cell lines. The activation of multiple pathways by hypothermia highlights the potential diversity of its therapeutic mechanisms. We show that, contrary to the predictions of the thermodynamic hypothesis, mild hypothermia can activate regulatory factors that govern cellular coping with stressors. Evidence suggesting that hypothermia is able to augment stress response in mammalian cell lines motivates to inspect corresponding mechanisms more closely in animal studies.
